China Pharmaceutical Contract Manufacturing Market Size to Reach $90.8 Billion by 2035

China pharmaceutical contract manufacturing market size reached $33.9 billion in 2025 and is projected to expand to $90.8 billion by 2035, growing at a CAGR of 10.4% during the forecast period (2026–2035). Market growth is supported by expanding pharmaceutical outsourcing, rising demand for biologics manufacturing, and cost advantages in large-scale drug production.

Key Market Drivers

• Increasing outsourcing by global pharmaceutical companies to reduce production costs.
• Growing demand for biologics and complex drug manufacturing capabilities.
• Expansion of domestic pharmaceutical innovation and R&D activities.
• Regulatory reforms supporting contract development and manufacturing organizations.
• Rising prevalence of chronic diseases increasing drug production needs.

Browse the full report description of “China Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report By Manufacturing Process Type (Sterile Manufacturing, and Non-Sterile Manufacturing), By Product Type (Over-The-Counter (OTC) Drugs, Active Pharmaceutical Ingredients (API), Finished Dosage Formulation, and Others), By Route of Administration (Oral Administration, Inhaled Administration, Parenteral Administration, and Others), By Service (R&D, Manufacturing, and Non-Clinical Service) Forecast, (2026-2035)” Of https://www.omrglobal.com/industry-reports/china-pharmaceutical-contract-manufacturing-market

Regional Analysis

China represents a central hub for pharmaceutical contract manufacturing within the Asia-Pacific region due to its large industrial base, skilled workforce, and supportive policy environment. Government initiatives aimed at strengthening domestic drug innovation and supply chain resilience continue to encourage investment in advanced manufacturing facilities. Regulatory authorities in China have implemented reforms to improve quality standards and accelerate approval timelines, which supports international partnerships and export-oriented production. The country’s expanding biologics sector and increasing demand for sterile manufacturing capabilities further contribute to market growth.

Competitive Landscape

Key companies operating in the china pharmaceutical contract manufacturing market include Apeloa Pharmaceutical Co., Ltd., Asymchem Laboratories (Tianjin) Co., Ltd., Pharmaron (Beijing) Co., Ltd., WuXi AppTec Co., Ltd., WuXi Biologics Cayman Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Market Developments

• In November 2025, WuXi XDC Cayman Inc. signed a Memorandum of Understanding with Standard Chartered Bank (China) Limited to form a comprehensive strategic partnership. The collaboration aims to support the company’s global expansion, cross-border financial planning, and development of the bioconjugate contract research, development, and manufacturing ecosystem.

• In November 2025, WuXi XDC Cayman Inc. highlighted its expanding global customer base and project pipeline in the ADC contract manufacturing sector. Company disclosures indicated partnerships with numerous major pharmaceutical firms and support for multiple investigational drug applications.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By manufacturing process type
  • By product type
  • By route of administration
  • By service
• Region Covered-
  • China

Competitive Landscape- Apeloa Pharmaceutical Co., Ltd., Asymchem Laboratories (Tianjin) Co., Ltd., Pharmaron (Beijing) Co., Ltd., WuXi AppTec Co., Ltd., WuXi Biologics Cayman Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

China Pharmaceutical Contract Manufacturing Market Report Segment

By manufacturing process type

• Sterile manufacturing
• Non-sterile manufacturing

By product type

• OTC
• API
• Finished dosage formulation
• Others

By route of administration

• Oral
• Inhaled
• Parenteral
• Others

By service

• R&D
• Manufacturing
• Non-clinical

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/china-pharmaceutical-contract-manufacturing-market